Article

Alcon, Johnson & Johnson to face off in intellectual property dispute

After a US District judge rules against request for preliminary injunction, Johnson & Johnson Vision moves forward with litigation in several countries, including the United States, to resolve intellectual property disputes against Alcon.


Johnson & Johnson Vision (J&J Vision) is pursuing litigation in several countries, including the United States, to resolve an intellectual property dispute against Alcon, according to a prepared statement.

The lawsuit, filed in the U.S. District Court in Delaware, alleges that Alcon’s LenSx Femtosecond Laser Systems infringe on J&J Vision’s JJV's copyrighted source code as well as certain patents relating to the CATALYS Precision Laser System.

Alcon has also asserted patent infringement claims against J&J in the United States and in Europe relating to J&J’s Catalys femtosecond laser system. Both parties have asserted that the other’s patents are invalid, and both parties deny infringing the other party’s patent rights.

In February, J&J Vision filed a motion for a preliminary injunction against Alcon in its U.S. case, asking the court to prevent Alcon from selling new and refurbished LenSx femtosecond laser systems while the suit is pending.

Last week, the court ruled that a preliminary injunction was not warranted because the injuries claimed by J&J, if proven at trial, would be adequately compensated by money damages and J&J waited more than six years to file suit.

Alcon released a statement today saying the company “is confident in its position and will continue to defend its rights and prosecute its claims of patent infringement against J&J Vision in the United States and Europe.”

Alcon also was buoyed by the District Court ruling denying J&J Vision’s request for a preliminary injunction.

“For the benefit of customers and patients around the world, and consistent with that ruling, Alcon will continue to sell, install and service LenSx Laser Systems,” the statement concluded. “As a matter of corporate policy, we have no further comment on pending or ongoing litigation.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.